Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 9/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | NNMT | P40261 | 3/20 | 0.33 |
| ▸ | RHOC | P08134 | 3/20 | 0.33 |
| ▸ | RHOA | P61586 | 3/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523366 | 0.91 | F2 (0.34) | DDR1F2BDKRB1 | |
| SCHEMBL3407614 | 0.87 | CACNA2D1 (0.34) | UTS2RF2 | |
| SCHEMBL3404903 | 0.86 | RHOC (0.42) | DDR1F2NNMTRHOCRHOA | |
| SCHEMBL3429829 | 0.85 | UTS2R (0.40) | DDR1UTS2RF2NNMTRHOC | |
| SCHEMBL6525306 | 0.84 | F2 (0.35) | DDR1F2BDKRB1 | |
| SCHEMBL3430317 | 0.84 | DDR1 (0.38) | DDR1UTS2RF2NNMTRHOC | |
| SCHEMBL3408843 | 0.84 | UTS2R (0.39) | DDR1UTS2RF2NNMTRHOC | |
| SCHEMBL3406266 | 0.84 | UTS2R (0.39) | DDR1UTS2RF2NNMTRHOC | |
| SCHEMBL976068 | 0.83 | UTS2R (0.38) | DDR1UTS2RF2NNMTRHOC | |
| SCHEMBL977000 | 0.83 | RHOC (0.41) | DDR1F2NNMTRHOCRHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | claimed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | claimed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | claimed |
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | QDPR, NHERF1, GABRR1 | DDR1 4094/4885UTS2R 496/4885F2 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.